Bondoc si Asociatii has advised BFS Molecular on the sale of its assets, including intellectual property, to CareDx. DLA Piper advised CareDx on the deal.
BFS Molecular is a software company focusing on next-generation sequencing-based patient testing solutions. Headquartered in South San Francisco, CareDx is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.
The Bondoc si Asociatii team was led by Partner Monica Iancu and included Managing Counsels Daniela Gladunea and Horatiu Dumitru.
